The Readout Loud
STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
Mentioned books
Jul 12, 2018 • 25min
Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'
Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?
Jul 5, 2018 • 20min
Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts
Adam and Damian recap the past six months in biotech. Investor and philanthropist, Sheff Station, stops by and gives tips on how to become a day trader, and analysts questioning their very existence.
Jun 28, 2018 • 23min
Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China
How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca explains how drugs are priced in China.
Jun 21, 2018 • 26min
Episode 16: Sarepta's big week, Theranos' legal woes and parsing AI hype
Is Sarepta Therapeutics worth $10 billion? Will Theranos' Elizabeth Holmes go behind bars? And how does AI fit into biotech?
Jun 14, 2018 • 24min
Episode 15: Problematic parties, Nitpicking NASH, and an opioid documentary from STAT
The problem with the topless dancers at PABNAB. Are investors overestimating the market for fatty liver drugs? And how many lives do biotech entrepreneurs get?
Jun 7, 2018 • 27min
Episode 14: Twitter vitriol, biotech jargon, and the plight of the CEO
Why is Twitter so mean to Axovant? Adam teaches a crash course on biostatistics. And will sci-fi gene and cell therapies ever go mainstream.
May 31, 2018 • 23min
Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO?
Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?
May 24, 2018 • 28min
Episode 12: Ebola should worry you, again; 23andMe's World Cup whoops; Don't drink sunscreen
How worried should you be about Ebola? Can the government lower drug prices without hurting the drug industry? And is socceromics a thing? Listen this week to find out.
May 17, 2018 • 23min
Episode 11: Inside the Theranos collapse, Valeant's latest legal lumps, and a few biotech hot takes
What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?
May 10, 2018 • 22min
Episode #10: Cohen, Trump, Novartis, oh my; Spark + Amish; Genetic testing at your doc's office?
On today's show, we dig into the no good, very bad day Novartis had when the world got wind of its ties to President Trump's personal attorney, a discussion of how the world's biggest cancer conference used to be the Wild West for investors, and an exploration of one health system's plan to bring genomics to the masses. Also STAT's Eric Boodman joins us to talk about how a pricey new gene therapy has created a fascinating situation in Amish country.
